- Home
- BMY
as 02-21-2025 4:00pm EST
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
| Founded: | 1887 | Country: | United States |
| Employees: | N/A | City: | PRINCETON |
| Market Cap: | 115.3B | IPO Year: | N/A |
| Target Price: | $58.00 | AVG Volume (30 days): | 11.5M |
| Analyst Decision: | Hold | Number of Analysts: | 14 |
| Dividend Yield: | Dividend Payout Frequency: | Quarterly | |
| EPS: | -4.41 | EPS Growth: | N/A |
| 52 Week Low/High: | $39.35 - $61.10 | Next Earning Date: | 02-06-2025 |
| Revenue: | $48,300,000,000 | Revenue Growth: | 7.32% |
| Revenue Growth (this year): | -0.97% | Revenue Growth (next year): | -7.79% |
Latest Bristol-Myers Squibb Company News
BMY Breaking Stock News: Dive into BMY Ticker-Specific Updates for Smart Investing
Argus Research
2 days ago
Daily – Vickers Top Buyers & Sellers for 02/20/2025
Clinical Trials Arena
2 days ago
BMS’ Opdivo plus chemotherapy shows OS benefit in Phase III NSCLC study
Benzinga
2 days ago
Bristol Myers Cancer Drug Opdivo In Combination With Chemo Shows Improved Overall Survival In Certain Patients With Lung Cancer
MT Newswires
3 days ago
Amneal Pharmaceuticals Launching Mesalamine, Gets US FDA Approval for Lenalidomide
MT Newswires
3 days ago
Bristol-Myers Squibb's Lung Cancer Drug Shows Significant Increase in Patients' Overall Survival
Business Wire
3 days ago
Bristol Myers Squibb Announces Opdivo® Plus Chemotherapy as the First and Only Neoadjuvant-Only Immuno-Oncology Therapy to Demonstrate Statistically Significant and Clinically Meaningful Overall Survival in Resectable Non-Small Cell Lung Cancer
TipRanks
4 days ago
Bristol Myers announces new five-year results from POETYK PSO trial
MT Newswires
4 days ago
Redburn Atlantic Adjusts Price Target on Bristol-Myers Squibb to $54 From $52, Maintains Neutral Rating
Compare BMY vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "BMY Bristol-Myers Squibb Company - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.